FUB-144 (also known as FUB-UR-144) is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor[1] and has been sold online as a designer drug.[2] It is an analogue of UR-144 and XLR-11 where the pentyl chain has been replaced with fluorobenzyl.

In the United States, FUB-144 was temporarily emergency scheduled by the DEA in 2019.[3] and made a permanent Schedule I Controlled Substance on April 7, 2022.[4]

Sweden's public health agency suggested classifying FUB-144 as hazardous substance on March 24, 2015.[5]

See also

References

  1. ^ Marusich JA, Gamage TF, Zhang Y, Akinfiresoye LR, Wiley JL (October 2022). "In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists". Pharmacology, Biochemistry, and Behavior. 220: 173467. doi:10.1016/j.pbb.2022.173467. PMC 9837865. PMID 36154844.
  2. ^ "FUB-144". Southern Association of Forensic Scientists. Archived from the original on 27 September 2015. Retrieved 23 July 2015.
  3. ^ "Schedules of Controlled Substances: Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 into Schedule I". Federal Register.
  4. ^ "Schedules of Controlled Substances: Placement of 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA, and FUB-144 in Schedule I" (PDF). Federal Register. 87 (67). 7 April 2022.
  5. ^ "Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 23 July 2015.
Allikas: https://en.wikipedia.org/wiki/FUB-144
No tags for this post.